US OptionsDetailed Quotes
ARGX240816C380000
- 71.40
- 0.000.00%
15min DelayTrading Jul 9 09:38 ET
0.00High0.00Low
0.00Open71.40Pre Close0 Volume23 Open Interest380.00Strike Price0.00Turnover39.05%IV-3.09%PremiumAug 16, 2024Expiry Date85.81Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9802Delta0.0010Gamma5.32Leverage Ratio-0.0969Theta0.2584Rho5.21Eff Leverage0.0593Vega
argenx SE Stock Discussion
📌 This week’s PDUFAs:
$Merck & Co(MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
$Harmony Biosciences(HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US)$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...
$Mingteng International(MTEN.US)$ buy
no 1. $Biogen(BIIB.US)$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US)$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US)$ all time low 7 USD
no5. $argenx SE(ARGX.US)$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2 ...
Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF)
Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering.
Unexpectedly Strong Impact of Corticosteroids
The primary setback was the ...
No comment yet